Jamison Private Wealth Management Inc. Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Jamison Private Wealth Management Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,429 shares of the company’s stock after selling 756 shares during the period. Johnson & Johnson comprises 1.3% of Jamison Private Wealth Management Inc.’s holdings, making the stock its 23rd biggest holding. Jamison Private Wealth Management Inc.’s holdings in Johnson & Johnson were worth $6,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $4,609,399,000. Journey Strategic Wealth LLC lifted its position in shares of Johnson & Johnson by 161,420.2% in the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock worth $1,204,404,000 after purchasing an additional 7,271,978 shares during the period. Morgan Stanley lifted its position in Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares during the last quarter. Finally, Barclays PLC lifted its position in Johnson & Johnson by 61.0% during the second quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock valued at $1,868,351,000 after acquiring an additional 4,278,512 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.4 %

JNJ opened at $157.96 on Thursday. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The company has a fifty day moving average of $158.76 and a two-hundred day moving average of $156.69. The stock has a market capitalization of $380.65 billion, a price-to-earnings ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the company earned $2.35 earnings per share. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were given a $1.19 dividend. The ex-dividend date was Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Raymond James increased their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.